BioWorld

Dec. 9, 2005

Protherics Sends Sepsis Drug To AstraZeneca In $341M Deal

In its most significant deal to date, Protherics plc licensed rights to its late-stage sepsis drug candidate to AstraZeneca plc for a potential £195 million (US$341 million). (BioWorld Today) Read More

Feeling Lucentis Pressure, QLT Cuts Staff, Restructures

Synergistic With Velcade, NPI-0052 Heading To Clinic

Dyax Starts Pivotal Phase III With HAE Treatment DX-88

GTC Moving ATryn Forward Via Stock Deal Worth $16.7M

U.S. Patent Disclosures

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 9, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...